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Objective:  Assess  quality-of-life  results  in patients  who  have  undergone  extensive  curative  surgery  for
spinal  tumor  and  compare  them  to  the  general  population  in France.
Introduction:  Life  expectancy  is not  the  only  criterion  to assess  the  outcomes  after  massive  tumor  resec-
tions.  Residual  quality  of life  is  also  crucial.  An  indication  for major  surgery  for spinal  tumor  should  take
the  patient’s  long-term  functional  status  into  account,  but the  literature  is limited  on  this question.
Materials  and methods:  Twenty-ﬁve  living  patients  from  a group  of  120  operated  were  assessed,  all  of
whom were  operated  on  by the  same  surgeon  between  1984  and  2007.  The  mean  follow-up  was  9  years
(range,  3–25  years).  The  mean  age  at surgery  was  49  years.  The  patients  completed  different  functional  and
quality-of-life  questionnaires:  the  Oswestry  Disability  Index  version  2 (ODI),  the PROLO,  the  Karnofsky
Index  of performance  status  (KI),  the  Eastern  Cooperative  Oncology  Group  performance  status  (ECOG),
the Short  Form-36  Health  Survey  (SF-36),  and the  EuroQol-5  Dimensions  (EQ5D).  In  addition,  each  patient
was clinically  and  radiographically  evaluated.  Subgroups  were  identiﬁed  considering  the  number  of  levels
resected  and  histology.  Their  results  on  the  SF-36  were  compared  with  the  results  from  the  general
population  in France.
Results:  The  mean  PCS  (physical  component  summary  of the SF-36)  was 52.4,  the  MCS  (mental  component
summary,  the  psychological  component  of the  SF-36)  was  47.7,  the  ODI was  18.2, the PROLO  was  7,  the
ECOG  was  1,  and the  KI  was  80%.  The  resections  at three  levels  were associated  with  worse  results  in
terms  of quality  of life,  but overall,  the  results  were  similar  to  the  French  general  population  data  for  all
categories  of  the  SF-36.
Conclusion:  Appropriate  indications  for massive  spinal  resection  give  good  oncological  and  functional
results.  Although  the expected  life expectancy  justiﬁes  this  aggressive  surgery,  postoperative  quality  of
life  shows  that  it can  also  be  successful  on  a functional  level.
Level  of evidence:  Level  IV; retrospective  clinical  study.. Introduction
Quality-of-life (QoL) assessment has become an indispensable
ool to measure patients’ experience after surgery. These long-
eglected data should be taken into account in the implementation
f therapeutic strategies in cancer treatment [1]. A large number
f QoL assessments after cancer treatment have been carried out
2–5]. However, the evaluation of QoL after partial or total verte-
rectomy for tumors remains very limited. We  found no articles
n the literature that had examined this subject over the medium
r long-term. Partial vertebrectomy (or hemi-vertebrectomy) and
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total vertebrectomy are interventions with high morbidity whose
risk–beneﬁt ratio can be unfavorable. It is therefore essential to
determine its value taking into account objective evaluations such
as the different QoL evaluation scores. The objective of this study
was to assess the long-term QoL of patients after en-block ver-
tebrectomy for tumor and to compare it to the QoL of a normal
reference population.
2. Patients and methods
Between 1984 and 2007, 120 patients underwent partial or total
vertebrectomy in our department by the same operator. The 25
living patients (20.8%) at the minimum follow-up of 3 years were
reviewed and questioned by two independent observers. In addi-
tion, in the overall series, three patients were lost to follow-up. The
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ample included 10 females and 15 males. The mean follow-up was
12 ± 70 months, i.e., 9.4 years (range, 36–312 months).
The inclusion criteria in the series were partial or total cervi-
othoracic, thoracic, or lumbar vertebrectomy for primary tumor
isease (13 patients), or for primary lung tumor with vertebral
nvasion or Pancoast Tobias syndrome (PCT) (nine patients), or
or isolated metastasis (three patients). Resections in the mid-
r upper-cervical regions were not retained because of the great
ifﬁculty of obtaining radical resection on the oncological level.
he resection criteria were based on a preoperative histological
iagnosis. Computed tomography (CT) and magnetic resonance
maging (MRI) evaluated vertebral invasion and the adjacent soft
issues. The absence of adenopathies was required for PCT and
etastases, as well as the absence of other secondary locations
or metastases. After initial assessment of operability, the surgical
ndication was validated in a multidisciplinary meeting. Vertebrae
ere resected following the principle of en-bloc vertebrectomy
escribed by Mazel [6], a technique derived from Roy-Camille
7,8] and Stener’s [9–11] technique. In cases of lung tumors with
ancoast-Tobias-type locoregional vertebra invasion, a ﬁrst phase
f anterior release systematically preceded the second phase of
osterior tumor exeresis and stabilization. This was done either by
horacoscopy, a supraclavicular approach [12], or by thoracotomy.
hese procedures were always performed by the thoracic surgery
eam for the ﬁrst phase of anterior release.
This study was conducted over a 2-year period so that patients
perated on many years before could be included. During this
eriod, of the 25 patients included in the study two had died by the
nd of the study. We  decided to retain them in the study because
eath occurred for a cause that was not related to the tumor dis-
ase and they had been followed up for 26 and 12 years, and we
ere able to obtain the data necessary for this study before their
eath.
The general data – age, gender, type of tumor, characteristics
f surgery – were collected from the patient ﬁle. The mean age
f the patients at the time of vertebrectomy was 49.5 ± 13.4 years
range, 26–68 years). In the majority of cases, the lesions were
ntracompartmental according to the Tomita classiﬁcation [13]. The
ean Tomita prognosis score was 3. We  divided the patients into
hree groups: primary tumors, PCTs, and metastases (Tables 1–3).
artial vertebrectomy was performed for 12 patients and total ver-
ebrectomy for 13. One patient underwent total vertebrectomy
t one level and partial vertebrectomy on the supra- and subja-
ent vertebrae. She was included in the total vertebrectomy group.
wenty-two vertebrectomies were performed at the thoracic level
nd three at the lumbar level. Of the 25 patients, 13 presented pri-
ary tumors, nine PCTs, and three isolated metastases. Finally, in
erms of the number of resected vertebrae, ten patients had one
ertebra resected, eight had two vertebrae resected, six had three,
nd one had ﬁve.
The functional and QoL evaluation made use of the following
cores: the Oswestry Disability Index version 2 (ODI), the PROLO,
he Karnofsky Index performance status (KI), the Eastern Coopera-
ive Oncology Group performance status (ECOG) for function, and
he Short Form-36 health Survey (SF-36) and EuroQol 5 Dimen-
ions (EQ5D) for QoL. The scores were selected to have several
ecognized scales at our disposal, associating scores targeted to
he spine (ODI) with scores covering general functional capaci-
ies (Karnofsky and ECOG), the socioeconomic repercussions of the
isease (PROLO), and QoL (SF-36 and EQ5D) so as to obtain an over-
ll view of the patient and compare the coherence of the study’s
esults.The ECOG [14] score and the Karnofsky Index [15–17] allow one
o study the performance index of oncology patients. An ECOG less
han 2 is associated with satisfactory QoL [18], whereas a KI of at
east 80% is compatible with normal life without assistance.Surgery & Research 100 (2014) 119–126
The PROLO score is the sum of the economic and functional sta-
tuses, each scored from 1 to 5. A score between 7 and 8 is good, and
between and 9 and 10 is excellent [19].
The ODI comprises ten questions, each with six levels of
responses ranging from 0 to 5. A review of the literature of the ODI
scores showed that there was a mean between 10 and 19 [20] in the
normal population. The ODI can be correlated with daily activities.
The EQ5D is a QoL score that assesses ﬁve parameters (mobil-
ity, autonomy in personal hygiene, autonomy in daily activities,
pain, and anxiety-depression) on three levels. It is a reliable score
[21], simple, and useful for the socioeconomic and QoL evaluation
according to Choi et al. [22]. For each parameter studied, 1 corre-
sponds to the optimal response, 2 to the intermediate response,
and 3 to the worst situation.
The SF-36 was  used in its second international version as trans-
lated into French. This reliable score has been validated [23,24].
The SF-36 comprises 36 items grouped into eight scales: PF (phys-
ical functioning), RP (role physical), BP (bodily pain), GH (general
health), VT (vitality), SF (social functioning), RE (role emotional),
and MH  (mental health). The latter score is particularly useful
because for these eight scales we  have mean values for the normal
population in France [25], which allowed us to compare them with
the study results using a Student t-test. It is the repeated obser-
vation of the results of the factorial analysis of the eight SF-36
subscales that led its designers to construct two overall scores: the
mental component summary (MCS) and the physical component
summary (PCS).
3. Results
3.1. Clinical, radiological, and biological follow-up
Only one patient’s reconstruction graft did not heal, requiring
surgical revision 2 years postoperative, with bone healing obtained
at 11 years of follow-up. Three patients presented persistent pro-
gression of their general disease, with no alteration of their QoL.
Three patients presented brachial neuralgia related to the intraop-
erative section of nerve roots contributing to the lower trunk of the
superﬁcial brachial plexus. They were treated medically. This is cer-
tainly the main postoperative complication observed in this surgery
at the cervicothoracic junction where the C8 and/or T1 nerve roots
were sacriﬁced.
3.2. Functional scores
3.2.1. ODI and PROLO scores
The mean ODI was  18.2 ± 15.6% (range, 0–60). Sixteen patients
out of 25 had an ODI score between 0 and 20 (Fig. 1). The highest
ODI rates, 50 and 60, respectively, were found in two patients who
had undergone resection at three levels.
The mean PROLO was  7 ± 3 (range, 2–10). Fourteen patients
out of 25 had good to excellent scores (Fig. 2). Nine patients
were retired when the neoplasia diagnosis was made, and another
patient retired after surgery; questioning these patients showed
that they were all active. Four are on disability. Eight had resumed
work in their initial position (ofﬁce work for the most part) and
three had their work station adapted.
3.2.2. 2- KI and ECOG scores
The mean KI was 80 ± 10.7% (range, 60–100). Twenty patients
had at least 80% on the KI (Fig. 3). The lowest KI score was  60%, found
in three patients who had undergone vertebrectomy at three levels.
The mean ECOG was  1 ± 0.5 (range, 0–2). There were no ECOG
scores greater than 2. Twenty-two patients had an ECOG score
lower than or equal to 1 (Fig. 4).
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Table 1
Patients (no preoperative radiotherapy) operated for primary tumors.
Number Age Gender Histology HPS Type of
resection
Fixation level and type
of  bone graft
Radicular
resection
Surgery
duration (h)
Bleeding
(cm3)
Neoadjuvant
chemotherapy
Duration of
hospital stay
(days)
Maximum
follow-up
(months)
1a 28 M Hemangiopericytoma Yes Partial T4, T5,
T6, T7, T8
T3–T9. RRC+ anterior
autograft (ﬁbula)
No 12 4000 Yes 15 190
2  39 M Epidural chordoma Yes Total T3, T4 C7-T7 Agora+ iliac
tricortical autograft
T4 left+ T4, T5
right
7 700 No 30 150
3  68 F Benign Schwannoma No Partial T11 T10, T12 Agora+ iliac
crest cancellous
autograft
T11 left 2.5 750 No 16 120
4  31 F Ganglioneuroma Non Partial T2, T3 C7–T5. RRC+
Cancellous autograft
T1, T2 left 7.5 2600 No 12 102
5  45 M Plasmocytoma Yes Total T5 T3–T7 Twinﬂex+
femoral head allograft
T5 right 4.5 400 No 10 187
6a 32 M Plasmocytoma No Total L5 L3–S3 Agora+
Harms Mesh+
Fibula+ iliac crest
tricortical autograft
No 6 5900 No 15 63
7a 60 F Fibrous dysplasia No Total T4 T1–T7 Agora+ femoral
head allograft
T4 right and
left
3.3 650 No 7 59
8  45 M Chordoma Yes Total L1 T11–L3 Agora+ femoral
head allograft
L1, L2 left + T12,
L1 right
3 1200 No 15 45
9a 26 F Giant-cell tumor No Total T3 C7–T6 Agora+ femoral
head allograft
T3, T4 left 10 1400 No 21 43
10a 65 F Plasmocytoma No Total T8 T6–T10 Agora+
Harms+ iliac crest
cancellous autograft
No 8 3300 No 7 38
11a 67 F Epithelioid
hemangioma
Yes Total T5+
Partial T6, T7
T3–T10 Agora+
Harms+ iliac crest
cancellous autograft
T5, T6, T7 right
and left
4.5 3000 No 30 36
12a 46 M Vertebral
chondrosarcoma
No Total T1, T2 C6–T4 RC+ femoral
autograft
No 8 4000 No 30 264
13  45 M Aneurysmal cyst No Total T4 T3–4 right and
left
8 3000 No 25 312
RC: Roy-Camille; HPS: history of previous surgery.
a Embolization.
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Table 2
Patients operated for PCT (Pancoast-Tobias). Pre-, intra-, and postoperative evaluations.
Number Age Gender Histology Resection
margin
Type of
resection
Number
of levels
Fixation levels and
type of bone graft
Radicular
resection
Surgery
duration
(h)
Bleeding
(cm3)
Preoperative
radiotherapy
Chemotherapy Maximum
follow-up
(months)
1 62 M AdenoK Healthy Partial T1 T2 T3 3 C5-T5/RRC No 9 1600 No No 144
2  47 M AdenoK Healthy Total T4T5T6 R 3  T1-T9/Agora+ ﬁbular
autograft
T4, T5, T6 right 11.5 2000 No Neoadjuvant 156
3  39 F AdenoK Uncertain Partial T1, T2,
T3 R
3 C6–T5(RRC)+ iliac crest
cancellous autograft
C8, T1, T2, T3
right
9.5 −72,000a No Neoadjuvant 150
4  50 M AdenoK Healthy Partial T2, T3 R 2 C6–T5 Agora+ iliac
crest cancellous
autograft
T2, T3 right 7 2000 No Yes 110
5  46 M AdenoK Healthy Total T2, T3 2 C6–T6 Agora+
Femoral head allograft
T1, T2, T3 right 11 2300 No Yes 88
6  39 F Epidermoid
carcinoma
Healthy Partial T1, T2 L 2 C6–T4 Agora+ iliac
crest cancellous
autograft
T1, T2 left 7 2000 Yes Yes 81
7  55 M Epidermoid
carcinoma
Healthy Partial T2, T3,
T4 R
3 T1–T6 Agora+ iliac
crest cancellous
autograft
T3, T4, T5 right 5.5 2100 Yes Neoadjuvant 61
8  55 M Epidermoid
carcinoma
Healthy Partial T1, T2 L 2 C6-T4 Agora+
Cancellous tricortical
autograft
C8, T1, T2 left 4 1300 Yes Yes 60
9a 47 M Epidermoid
carcinoma
Healthy Partial T1, T2,
T3
3  C6–T5 Agora T1, T2, T3
right+
anastomosis
C8–T1
No Yes 100
RC: R Roy-Camille; AdenoK: Adenocarcinoma.
a Embolization.
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Table 3
Patients with single metastases.
Number Age Gender Histology HPS Type of
resection
Fixation levels and
type of bone graft
Radicular
resection
Surgery
duration
(h)
Bleeding
(cm3)
Pre-op Rx
therapy
Pre-op
chemotherapy
Duration of
hospital stay
(days)
Maximum
follow-up
(months)
1 72 F Pulmonary
adenoK
No Partial T2, T3 C6–T5. Agora
Cancellous + tricortical
iliac
Autograft
T2, T3, T4 right 6 400 No No 14 120
2a 68 F Mammary
adenoK
Yes Partial T2 L C6-T5 Agora+
Tricortical iliac crest
autograft
T1, T2 left 3 1300 Yes Yes 10 93
3a 62 M Neuroendocrine
tumor
Yes Total T12 T10-L3 Agora+
Harms+ iliac crest
cancellous autograft
T11, T12 right+
T10, T11 left
4.5 700 No No 15 37
HPS: history of previous surgery; AdenoK: adenocarcinoma.
a Embolization.
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Fig. 1. ODI score a minimum 3 years after vertebrectomy.
Fig. 2. Prolo score a minimum 3 years after vertebrectomy.
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Fig. 4. ECOG score a minimum 3 years after vertebrectomy.
Table 4
Value of SF-36 scales in present study compared to overall score of general popula-
tion  in France.
SF-36 variable Overall score of
general population
in France
Score in
present series
P-value
PF 84.45 78.2 NS
RP  81.21 83.00 NS
BP  73.39 76.40 NS
GH 69.13 75.60 NS
VT  59.96 67.60 NS
SF  81.55 74.40 NS
RE  82.13 74.40 NS
MH  68.47 70.80 NS
NS: non-signiﬁcant; PF: physical functioning; RP: role physical; BP: bodily pain; GH:
general health; VT: vitality; SF: social functioning; RE, role emotional; MH: mental
health.Fig. 3. Karnofsky Index a minimum 3 years after vertebrectomy.
.2.3. Quality-of-life scores
.2.3.1. SF-36. The PCS was 52.4 and the MCS  47.7. The SF-36 QoL
cores of the patients in the present study are comparable to those
f the normal population in France. We  demonstrated no signiﬁcant
ifferences in the eight SF-36 scores between the study’s patients
nd the values from the normal French population (Table 4 and
ig. 5).
However, analysis of the SF-36 brought out two  points that
hould be highlighted.Fig. 5. SF-36 score for the general population in France and for the study’s patients.
The resections at three levels, all types of resection combined,
were associated with the lowest QoL scores. For the PROLO scores,
4.7 and 8 were obtained, for the ODI 35.6, 11, and 15.4; the PCS,
47.4, 55.8, and 52; the MCS, 43.5, 48.7, and 48.8 with resections of
three, two, and one level, respectively (Fig. 6).
Primary tumors are associated with better QoL  scores than sec-
ondary tumors (Fig. 7 and Table 5).3.2.3.2. EQ5D. The majority of the patients (22/25) were able to
walk easily: the mean score for walking was  1.12 ± 0.33. The same
was true for personal hygiene, with a mean score of 1.16 ± 0.37.
C. Mazel et al. / Orthopaedics & Traumatology: 
Fig. 6. SF-36 variables after vertebrectomy of one, two, and three vertebrae.
Fig. 7. SF-36 variables as related to tumor type.
Table 5
Functional and quality-of-life scores as related to type of tumor.
Type of tumor PROLO ODI PCS MCS
Primary 7 15 52.9 47.4
M
m
c
r
t
r
a
f
i
p
o
4
4
e
b
iSecondary 6 22 51.8 48
PCT  6 24 53.8 45.2
ost patients described a few anxiety-depression problems, with a
ean at 1.56 ± 0.50 for this parameter. However, 11 patients (44%)
onsidered themselves lucky and happy to be alive. As for the occur-
ence of pain episodes, we obtained 1.6 ± 0.50. It should be noted
hat eight patients (32%) had nearly forgotten their back other than
are episodes of pain. Finally, 14 patients (56%) had no problems
ccomplishing tasks of daily living; we found a mean 1.44 ± 0.50
or this parameter.
Moreover, none of these patients demonstrated total incapac-
ty on any of the ﬁve parameters of the EQ5D. After surgery, ten
atients experienced considerable improvement in their auton-
my.
. Discussion
.1. Methodological analysis of the series: relevanceGiven the low number of subjects, this series can be consid-
red insufﬁciently signiﬁcant from a methodological point of view,
ut the fact that the phenomenon studied is rare must be taken
nto account. Based on a sample of fewer than 30 individuals, toSurgery & Research 100 (2014) 119–126 125
make statistically valid comparisons we had to assume that the
distribution of functional and QoL scores followed a normal distri-
bution in our study. Actually, only 13 observations were necessary
[26] to detect a one-standard deviation difference compared to the
norm, whereas this study included 25, allowing a type I error (5%)
and providing 90% statistical power, an acceptable consensus in
biomedical research. Comparison with the general population in
France is possible because 22 patients out of 25 in this study come
from this population; the three others originated from nearby Euro-
pean countries (Italy, the Netherlands, Spain).
Given the rarity of the phenomenon studied, the signiﬁcance
of the observations made within the different subgroups can also
be challenged. However, the fact that we showed that resection of
three vertebrae is associated with lower QoL scores compared to
resection of one or two vertebrae is not less signiﬁcant.
4.2. Choice of functional and quality-of-life scores
We deﬁne QoL as being: “the value assigned to the duration
of life as modiﬁed by the impairments, functional states, percep-
tions, and social opportunities that are inﬂuenced by disease, injury,
treatment, or policy” [27]. In evaluating QoL, one should take into
account patients’ culture and mental health.
QoL after vertebrectomy has rarely been assessed in the litera-
ture. We  believed it relevant to use several scores that we found
complementary, particularly since there was no score that, taken
alone, could assess well-being that covers both the physical and
psychological dimensions. A review of the literature showed how
difﬁcult it was to establish a consensual QoL evaluation form in the
context of spinal metastasis [28].
We ﬁrst wished to determine the general health of the patients
after vertebrectomy, a major surgical procedure. We  found the KI
score useful, but we added the ECOG score to verify the agreement
of the data. The results reported herein showed a mean 80% KI and
a mean ECOG score of 1.
After spinal surgery, it is valuable to evaluate the repercussions
of spinal pain on daily life. We  therefore opted to use the ODI,
which was  found to be a mean 18% in this study. This value is also
considered comparable to that in a normal population.
To evaluate patients’ socioeconomic situation, we retained the
PROLO score, which takes into account the patient’s ability to return
to an occupational activity. Returning to work is often related to the
patient’s age, and we  had to take into account that certain patients
were already retired at diagnosis or on disability for medical rea-
sons, and not due to the surgery itself. In fact, when questioning the
patients, we  noted that they presented little functional limitation.
The mean PROLO score was 7, which is a good result.
A health QoL questionnaire should meet certain criteria to be
considered reliable: it should take into account psychometric prop-
erties [29], be reliable [30], valid [30–32], reactive [33], practical
to use, and sensitive. The SF-36 questionnaire is described as being
the most widely studied generic QoL questionnaire [34]. The same is
true for the EQ5D, which was  designed as a self-administered ques-
tionnaire for the patient with the advantage of being simple and
concise. These two QoL questionnaires meet the above-cited crite-
ria that a QoL questionnaire should observe in assessing vertebral
metastases [22].
We found no study similar to the present study in terms of
methodology, which, in addition to the rarity of studies reporting
on vertebral tumors in general, made comparisons difﬁcult, partic-
ularly since today no health QoL questionnaire has been established
with consensus in the context of spinal tumors. For example, Street
designed the Spine Oncology Study Group Outcomes Questionnaire
(SOSGOQ) [35], comprising 27 items. This is a practical tool for
following up patients after spinal tumor surgery with the disadvan-
tage of focusing on spinal symptoms, which limits QoL assessment.
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eneric health QoL questionnaires in oncology also do not seem
dvantageous [22]: The Edmonton Symptom Assessment Scale
ESAS) [36] seems better adapted to terminal patients and therefore
nadequate for our series. The European Organization for Research
nd Treatment of Cancer Quality of Life Questionnaire C30 (EORTC
LQ-C30) has few correlations with the EQ5D [37], perhaps related
o the fact that its items seem better adapted to the general health
f oncology patients than to that of patients with spinal metastases.
. Conclusion
A vertebral tumor, whether it be primary or secondary, is a major
ital and functional challenge for the patient. When the surgical
ndication for partial or total vertebrectomy, whatever the number
f vertebrae to resect, is diagnosed, one must be aware that the
imple objective of prolonging the patient’s life cannot be the only
urpose of this surgery. The QoL that accompanies this survival is
n essential factor of the patient’s well-being. The good results in
he present series based on 25 patients demonstrate the relevance
f this attitude on condition that the surgical indication is well diag-
osed. The discussion of these cases in multidisciplinary meetings
s fundamental, as is collaboration with surgical teams possessing
omplementary skills. Radical resection surgery, in addition to pro-
iding more or less totally the solution to the oncological problem,
oes not compromise QoL, quite the opposite, as demonstrated in
his study in which the majority of long-term scores were close if
ot identical to the scores in the general population. It is there-
ore possible to conclude that en-bloc resection of tumor-invaded
ertebrae gives good long-term results and QoL.
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